Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Selenium in thyroid disorders — essential knowledge for clinicians


In the 1990s, selenium was identified as a component of an enzyme that activates thyroid hormone; since this discovery, the relevance of selenium to thyroid health has been widely studied. Selenium, known primarily for the antioxidant properties of selenoenzymes, is obtained mainly from meat, seafood and grains. Intake levels vary across the world owing largely to differences in soil content and factors affecting its bioavailability to plants. Adverse health effects have been observed at both extremes of intake, with a narrow optimum range. Epidemiological studies have linked an increased risk of autoimmune thyroiditis, Graves disease and goitre to low selenium status. Trials of selenium supplementation in patients with chronic autoimmune thyroiditis have generally resulted in reduced thyroid autoantibody titre without apparent improvements in the clinical course of the disease. In Graves disease, selenium supplementation might lead to faster remission of hyperthyroidism and improved quality of life and eye involvement in patients with mild thyroid eye disease. Despite recommendations only extending to patients with Graves ophthalmopathy, selenium supplementation is widely used by clinicians for other thyroid phenotypes. Ongoing and future trials might help identify individuals who can benefit from selenium supplementation, based, for instance, on individual selenium status or genetic profile.

Key points

  • Epidemiological data have suggested increased prevalence of benign thyroid disease with low selenium status, but the optimum range of intake is likely to be narrow, warranting a cautious approach to recommending selenium supplementation.

  • The effects of selenium supplementation might be mediated via repletion of antioxidant or immune-modulating selenoproteins, and polymorphisms in genes that encode selenoproteins might determine susceptibility to supplementation.

  • In chronic autoimmune thyroiditis, selenium supplementation reduces circulating levels of thyroid autoantibodies; however, evaluation of clinically important primary outcomes has not shown improvement and should be prioritized in future trials.

  • Observational studies have indicated that low selenium status is an iodine-independent risk factor for goitre; however, this finding has not been followed up by intervention trials in humans.

  • In Graves disease, selenium supplementation might facilitate biochemical restoration of euthyroidism and reduce ocular involvement, but these results need to be confirmed.

  • Treatment with selenium supplementation is widely used by clinicians across the spectrum of autoimmune thyroid diseases, despite the fact that it is recommended only in the treatment of mild Graves orbitopathy.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Selenoproteins are vital to the thyroid.
Fig. 2: Selenium intake in different countries.
Fig. 3: U-shaped relationship between selenium status and disease risk.


  1. 1.

    Schwarz, K. & Foltz, C. M. Selenium as an integral part of factor 3 against dietary necrotic liver degeneration. J. Am. Chem. Soc. 79, 3292–3293 (1957).

    CAS  Google Scholar 

  2. 2.

    Hatfield, D. L. & Gladyshev, V. N. How selenium has altered our understanding of the genetic code. Mol. Cell Biol. 22, 3565–3576 (2002).

    CAS  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Rayman, M. P. Selenium and human health. Lancet 379, 1256–1268 (2012). This article presents an overview of the different roles of selenium in relation to human health.

    CAS  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Clark, L. C. et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276, 1957–1963 (1996).

    CAS  PubMed  Google Scholar 

  5. 5.

    Lippman, S. M. et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301, 39–51 (2009).

    CAS  PubMed  Google Scholar 

  6. 6.

    Fan, Y. et al. Selenium supplementation for autoimmune thyroiditis: a systematic review and meta-analysis. Int. J. Endocrinol. 2014, 904573 (2014).

    PubMed  PubMed Central  Google Scholar 

  7. 7.

    Wichman, J., Winther, K. H., Bonnema, S. J. & Hegedus, L. Selenium supplementation significantly reduces thyroid autoantibody levels in patients with chronic autoimmune thyroiditis: a systematic review and meta-analysis. Thyroid 26, 1681–1692 (2016). This article is a systematic review of selenium supplementation trials in AIT.

    CAS  PubMed  Google Scholar 

  8. 8.

    Kohrle, J., Jakob, F., Contempre, B. & Dumont, J. E. Selenium, the thyroid, and the endocrine system. Endocr. Rev. 26, 944–984 (2005). This article is a comprehensive review of the roles of different selenoproteins in the endocrine system, including the thyroid.

    CAS  PubMed  Google Scholar 

  9. 9.

    Labunskyy, V. M., Hatfield, D. L. & Gladyshev, V. N. Selenoproteins: molecular pathways and physiological roles. Physiol. Rev. 94, 739–777 (2014).

    CAS  PubMed  PubMed Central  Google Scholar 

  10. 10.

    Schweizer, U. & Fradejas-Villar, N. Why 21? The significance of selenoproteins for human health revealed by inborn errors of metabolism. FASEB J. 30, 3669–3681 (2016).

    CAS  PubMed  Google Scholar 

  11. 11.

    Dumitrescu, A. M. & Refetoff, S. Inherited defects of thyroid hormone metabolism. Ann. Endocrinol. 72, 95–98 (2011).

    CAS  Google Scholar 

  12. 12.

    Schmutzler, C. et al. Selenoproteins of the thyroid gland: expression, localization and possible function of glutathione peroxidase 3. Biol. Chem. 388, 1053–1059 (2007).

    CAS  PubMed  Google Scholar 

  13. 13.

    Schomburg, L. Selenium, selenoproteins and the thyroid gland: interactions in health and disease. Nat. Rev. Endocrinol. 8, 160–171 (2012).

    CAS  Google Scholar 

  14. 14.

    Panicker, V. et al. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. J. Clin. Endocrinol. Metab. 94, 1623–1629 (2009).

    CAS  PubMed  Google Scholar 

  15. 15.

    Jo, S. et al. Type 2 deiodinase polymorphism causes ER stress and hypothyroidism in the brain. J. Clin. Invest. 129, 230–245 (2019).

    PubMed  Google Scholar 

  16. 16.

    Carlé, A., Faber, J., Steffensen, R., Laurberg, P. & Nygaard, B. Hypothyroid patients encoding combined MCT10 and DIO2 gene polymorphisms may prefer L-T3 + L-T4 combination treatment - data using a blind, randomized, clinical study. Eur. Thyroid J. 6, 143–151 (2017).

    PubMed  PubMed Central  Google Scholar 

  17. 17.

    Schomburg, L. & Köhrle, J. On the importance of selenium and iodine metabolism for thyroid hormone biosynthesis and human health. Mol. Nutr. Food Res. 52, 1235–1246 (2008).

    CAS  PubMed  Google Scholar 

  18. 18.

    Lin, J. C. et al. Glutathione peroxidase 3 gene polymorphisms and risk of differentiated thyroid cancer. Surgery 145, 508–513 (2009).

    PubMed  Google Scholar 

  19. 19.

    Curran, J. E. et al. Genetic variation in selenoprotein S influences inflammatory response. Nat. Genet. 37, 1234–1241 (2005).

    CAS  PubMed  Google Scholar 

  20. 20.

    Santos, L. R. et al. A polymorphism in the promoter region of the selenoprotein S gene (SEPS1) contributes to Hashimoto’s thyroiditis susceptibility. J. Clin. Endocrinol. Metab. 99, E719–E723 (2014). This case–control study shows increased risk of AIT with a polymorphism in the SELENOS gene. The polymorphism further increased the risk in males, suggesting sexual dimorphism.

    CAS  PubMed  Google Scholar 

  21. 21.

    Johnson, C. C., Fordyce, F. M. & Rayman, M. P. Symposium on ‘Geographical and geological influences on nutrition’: factors controlling the distribution of selenium in the environment and their impact on health and nutrition. Proc. Nutr. Soc. 69, 119–132 (2010).

    CAS  PubMed  Google Scholar 

  22. 22.

    Institute of Medicine. Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids (National Academies Press, 2000).

  23. 23.

    EFSA Panel on Dietetic Products, Nutrition and Allergies. Scientific opinion on dietary reference values for selenium. EFSA J. 12, 3846 (2014).

    Google Scholar 

  24. 24.

    Rayman, M. P. Food-chain selenium and human health: emphasis on intake. Br. J. Nutr. 100, 254–268 (2008).

    CAS  PubMed  Google Scholar 

  25. 25.

    Rayman, M. P. The use of high-selenium yeast to raise selenium status: how does it measure up? Br. J. Nutr. 92, 557–573 (2004).

    CAS  PubMed  Google Scholar 

  26. 26.

    Achouba, A., Dumas, P., Ouellet, N., Lemire, M. & Ayotte, P. Plasma levels of selenium-containing proteins in Inuit adults from Nunavik. Environ. Int. 96, 8–15 (2016).

    CAS  PubMed  Google Scholar 

  27. 27.

    Swanson, C. A. et al. Human [74Se]selenomethionine metabolism: a kinetic model. Am. J. Clin. Nutr. 54, 917–926 (1991).

    CAS  PubMed  Google Scholar 

  28. 28.

    Rayman, M. P. et al. Effect of long-term selenium supplementation on mortality: results from a multiple-dose, randomised controlled trial. Free. Radic. Biol. Med. 127, 46–54 (2018). This was a randomized, controlled trial that questioned the safety of current selenium upper tolerable intake limits.

    CAS  PubMed  Google Scholar 

  29. 29.

    Whanger, P. D. Selenocompounds in plants and animals and their biological significance. J. Am. Coll. Nutr. 21, 223–232 (2002).

    CAS  PubMed  Google Scholar 

  30. 30.

    Rayman, M. P., Infante, H. G. & Sargent, M. Food-chain selenium and human health: spotlight on speciation. Br. J. Nutr. 100, 238–253 (2008).

    CAS  PubMed  Google Scholar 

  31. 31.

    Patterson, B. H. et al. Human selenite metabolism: a kinetic model. Am. J. Physiol. 257, R556–R567 (1989).

    CAS  PubMed  Google Scholar 

  32. 32.

    Fairweather-Tait, S. J., Collings, R. & Hurst, R. Selenium bioavailability: current knowledge and future research requirements. Am. J. Clin. Nutr. 91, 1484s–1491s (2010).

    CAS  PubMed  Google Scholar 

  33. 33.

    Francesconi, K. A. & Pannier, F. Selenium metabolites in urine: a critical overview of past work and current status. Clin. Chem. 50, 2240–2253 (2004).

    CAS  PubMed  Google Scholar 

  34. 34.

    Robinson, J. R., Robinson, M. F., Levander, O. A. & Thomson, C. D. Urinary excretion of selenium by New Zealand and North American human subjects on differing intakes. Am. J. Clin. Nutr. 41, 1023–1031 (1985).

    CAS  PubMed  Google Scholar 

  35. 35.

    Ashton, K. et al. Methods of assessment of selenium status in humans: a systematic review. Am. J. Clin. Nutr. 89, 2025S–2039S (2009).

    CAS  PubMed  Google Scholar 

  36. 36.

    Rayman, M. P. et al. Effect of selenium on markers of risk of pre-eclampsia in UK pregnant women: a randomised, controlled pilot trial. Br. J. Nutr. 112, 99–111 (2014).

    CAS  PubMed  PubMed Central  Google Scholar 

  37. 37.

    Rayman, M. P., Bode, P. & Redman, C. W. Low selenium status is associated with the occurrence of the pregnancy disease preeclampsia in women from the United Kingdom. Am. J. Obstet. Gynecol. 189, 1343–1349 (2003).

    CAS  PubMed  Google Scholar 

  38. 38.

    Duncan, A., Talwar, D., McMillan, D. C., Stefanowicz, F. & O’Reilly, D. S. Quantitative data on the magnitude of the systemic inflammatory response and its effect on micronutrient status based on plasma measurements. Am. J. Clin. Nutr. 95, 64–71 (2012).

    CAS  PubMed  Google Scholar 

  39. 39.

    Stefanowicz, F. A. et al. Erythrocyte selenium concentration as a marker of selenium status. Clin. Nutr. 32, 837–842 (2013).

    CAS  PubMed  Google Scholar 

  40. 40.

    European Accreditation–Eurolab–Eurochem Reference Materials Working Group. Accreditation EA-4/14 INF: The Selection and Use of Reference Materials (Eurachem, 2003).

  41. 41.

    Mita, Y. et al. Selenoprotein P-neutralizing antibodies improve insulin secretion and glucose sensitivity in type 2 diabetes mouse models. Nat. Commun. 8, 1658 (2017).

    PubMed  PubMed Central  Google Scholar 

  42. 42.

    Xia, Y., Hill, K. E., Byrne, D. W., Xu, J. & Burk, R. F. Effectiveness of selenium supplements in a low-selenium area of China. Am. J. Clin. Nutr. 81, 829–834 (2005).

    CAS  PubMed  Google Scholar 

  43. 43.

    Yang, G. Q. & Xia, Y. M. Studies on human dietary requirements and safe range of dietary intakes of selenium in China and their application in the prevention of related endemic diseases. Biomed. Environ. Sci. 8, 187–201 (1995).

    CAS  PubMed  Google Scholar 

  44. 44.

    Hughes, D. J. et al. Selenium status is associated with colorectal cancer risk in the European prospective investigation of cancer and nutrition cohort. Int. J. Cancer 136, 1149–1161 (2015).

    CAS  PubMed  Google Scholar 

  45. 45.

    Laclaustra, M., Navas-Acien, A., Stranges, S., Ordovas, J. M. & Guallar, E. Serum selenium concentrations and diabetes in U.S. adults: National Health and Nutrition Examination Survey (NHANES) 2003-2004. Environ. Health Perspect. 117, 1409–1413 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  46. 46.

    Burek, C. L. & Rose, N. R. Autoimmune thyroiditis and ROS. Autoimmun. Rev. 7, 530–537 (2008).

    CAS  PubMed  Google Scholar 

  47. 47.

    Smith, T. J. & Hegedus, L. Graves’ disease. N. Engl. J. Med. 375, 1552–1565 (2016). This comprehensive review on Graves disease includes updates on disease aetiology and pathogenesis.

    PubMed  Google Scholar 

  48. 48.

    Marino, M., Dottore, G. R., Leo, M. & Marcocci, C. Mechanistic pathways of selenium in the treatment of Graves’ disease and Graves’ orbitopathy. Horm. Metab. Res. 50, 887–893 (2018).

    CAS  PubMed  Google Scholar 

  49. 49.

    Rotondo Dottore, G. et al. Antioxidant actions of selenium in orbital fibroblasts: a basis for the effects of selenium in Graves’ orbitopathy. Thyroid 27, 271–278 (2017).

    CAS  PubMed  Google Scholar 

  50. 50.

    Nettore, I. C. et al. Selenium supplementation modulates apoptotic processes in thyroid follicular cells. Biofactors 43, 415–423 (2017).

    CAS  PubMed  Google Scholar 

  51. 51.

    Balázs, C. & Kaczur, V. Effect of selenium on HLA-DR expression of thyrocytes. Autoimmune Dis. 2012, 374635 (2012).

    PubMed  PubMed Central  Google Scholar 

  52. 52.

    Huang, Z., Rose, A. H. & Hoffmann, P. R. The role of selenium in inflammation and immunity: from molecular mechanisms to therapeutic opportunities. Antioxid. Redox Signal. 16, 705–743 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  53. 53.

    Avery, J. C. & Hoffmann, P. R. Selenium, selenoproteins, and immunity. Nutrients 10, 1203 (2018). A comprehensive review on the roles of selenoproteins in the immune system.

    PubMed Central  Google Scholar 

  54. 54.

    Wang, W. et al. Effects of selenium supplementation on spontaneous autoimmune thyroiditis in NOD.H-2h4 mice. Thyroid 25, 1137–1144 (2015).

    CAS  PubMed  Google Scholar 

  55. 55.

    Xue, H. et al. Selenium upregulates CD4+CD25+ regulatory T cells in iodine-induced autoimmune thyroiditis model of NOD.H-2h4 mice. Endocr. J. 57, 595–601 (2010).

    CAS  PubMed  Google Scholar 

  56. 56.

    McLachlan, S. M., Aliesky, H., Banuelos, B., Hee, S. S. Q. & Rapoport, B. Variable effects of dietary selenium in mice that spontaneously develop a spectrum of thyroid autoantibodies. Endocrinology 158, 3754–3764 (2017). This experimental study provided evidence that is consistent with increased risk of AIT with low selenium status.

    CAS  PubMed  PubMed Central  Google Scholar 

  57. 57.

    Contempre, B. et al. Effect of selenium supplementation in hypothyroid subjects of an iodine and selenium deficient area: the possible danger of indiscriminate supplementation of iodine-deficient subjects with selenium. J. Clin. Endocrinol. Metab. 73, 213–215 (1991).

    CAS  PubMed  Google Scholar 

  58. 58.

    Contempre, B. et al. Effect of selenium supplementation on thyroid hormone metabolism in an iodine and selenium deficient population. Clin. Endocrinol. 36, 579–583 (1992).

    CAS  Google Scholar 

  59. 59.

    Winther, K. H. et al. Does selenium supplementation affect thyroid function? Results from a randomized, controlled, double-blinded trial in a Danish population. Eur. J. Endocrinol. 172, 657–667 (2015).

    CAS  PubMed  Google Scholar 

  60. 60.

    Duffield, A. J., Thomson, C. D., Hill, K. E. & Williams, S. An estimation of selenium requirements for New Zealanders. Am. J. Clin. Nutr. 70, 896–903 (1999).

    CAS  PubMed  Google Scholar 

  61. 61.

    Thomson, C. D., McLachlan, S. K., Grant, A. M., Paterson, E. & Lillico, A. J. The effect of selenium on thyroid status in a population with marginal selenium and iodine status. Br. J. Nutr. 94, 962–968 (2005).

    CAS  PubMed  Google Scholar 

  62. 62.

    Rayman, M. P. et al. Randomized controlled trial of the effect of selenium supplementation on thyroid function in the elderly in the United Kingdom. Am. J. Clin. Nutr. 87, 370–378 (2008).

    CAS  PubMed  Google Scholar 

  63. 63.

    Hansen, P. S. et al. Genetic and environmental causes of individual differences in thyroid size: a study of healthy Danish twins. J. Clin. Endocrinol. Metab. 89, 2071–2077 (2004).

    CAS  PubMed  Google Scholar 

  64. 64.

    Derumeaux, H. et al. Association of selenium with thyroid volume and echostructure in 35- to 60-year-old French adults. Eur. J. Endocrinol. 148, 309–315 (2003).

    CAS  PubMed  Google Scholar 

  65. 65.

    Rasmussen, L. B. et al. Selenium status, thyroid volume, and multiple nodule formation in an area with mild iodine deficiency. Eur. J. Endocrinol. 164, 585–590 (2011).

    CAS  PubMed  Google Scholar 

  66. 66.

    Wu, Q. et al. Low population selenium status is associated with increased prevalence of thyroid disease. J. Clin. Endocrinol. Metab. 100, 4037–4047 (2015). This was a large, community-based study that confirms previously reported associations about increased risk of thyroid disease with low selenium status.

    CAS  PubMed  Google Scholar 

  67. 67.

    Ajjan, R. A. & Weetman, A. P. The pathogenesis of Hashimoto’s thyroiditis: further developments in our understanding. Horm. Metab. Res. 47, 702–710 (2015). A review on AIT pathogenesis, which discusses the importance of selenium.

    CAS  PubMed  Google Scholar 

  68. 68.

    Brix, T. H., Kyvik, K. O. & Hegedus, L. A population-based study of chronic autoimmune hypothyroidism in Danish twins. J. Clin. Endocrinol. Metab. 85, 536–539 (2000).

    CAS  PubMed  Google Scholar 

  69. 69.

    Hansen, P. S., Brix, T. H., Iachine, I., Kyvik, K. O. & Hegedus, L. The relative importance of genetic and environmental effects for the early stages of thyroid autoimmunity: a study of healthy Danish twins. Eur. J. Endocrinol. 154, 29–38 (2006).

    CAS  PubMed  Google Scholar 

  70. 70.

    Brix, T. H. & Hegedus, L. Twin studies as a model for exploring the aetiology of autoimmune thyroid disease. Clin. Endocrinol. 76, 457–464 (2012).

    CAS  Google Scholar 

  71. 71.

    Bulow Pedersen, I. et al. Serum selenium is low in newly diagnosed Graves’ disease: a population-based study. Clin. Endocrinol. 79, 584–590 (2013).

    Google Scholar 

  72. 72.

    Gärtner, R., Gasnier, B. C., Dietrich, J. W., Krebs, B. & Angstwurm, M. W. Selenium supplementation in patients with autoimmune thyroiditis decreases thyroid peroxidase antibodies concentrations. J. Clin. Endocrinol. Metab. 87, 1687–1691 (2002).

    PubMed  Google Scholar 

  73. 73.

    Gärtner, R. & Gasnier, B. C. Selenium in the treatment of autoimmune thyroiditis. Biofactors 19, 165–170 (2003).

    PubMed  Google Scholar 

  74. 74.

    Duntas, L. H., Mantzou, E. & Koutras, D. A. Effects of a six month treatment with selenomethionine in patients with autoimmune thyroiditis. Eur. J. Endocrinol. 148, 389–393 (2003).

    CAS  PubMed  Google Scholar 

  75. 75.

    Turker, O., Kumanlioglu, K., Karapolat, I. & Dogan, I. Selenium treatment in autoimmune thyroiditis: 9-month follow-up with variable doses. J. Endocrinol. 190, 151–156 (2006).

    CAS  PubMed  Google Scholar 

  76. 76.

    Mazokopakis, E. E. et al. Effects of 12 months treatment with L-selenomethionine on serum anti-TPO levels in patients with Hashimoto’s thyroiditis. Thyroid 17, 609–612 (2007).

    CAS  PubMed  Google Scholar 

  77. 77.

    Balázs, C. The effect of selenium therapy on autoimmune thyroiditis. Orv. Hetil. 149, 1227–1232 (2008).

    PubMed  Google Scholar 

  78. 78.

    Karanikas, G. et al. No immunological benefit of selenium in consecutive patients with autoimmune thyroiditis. Thyroid 18, 7–12 (2008).

    CAS  PubMed  Google Scholar 

  79. 79.

    Kvicala, J. et al. Effect of selenium supplementation on thyroid antibodies. J. Radioanal. Nucl. Chem. 280, 275–279 (2009).

    CAS  Google Scholar 

  80. 80.

    Nacamulli, D. et al. Influence of physiological dietary selenium supplementation on the natural course of autoimmune thyroiditis. Clin. Endocrinol. 73, 535–539 (2010).

    CAS  Google Scholar 

  81. 81.

    Krysiak, R. & Okopien, B. The effect of levothyroxine and selenomethionine on lymphocyte and monocyte cytokine release in women with Hashimoto’s thyroiditis. J. Clin. Endocrinol. Metab. 96, 2206–2215 (2011).

    CAS  PubMed  Google Scholar 

  82. 82.

    Krysiak, R. & Okopien, B. Haemostatic effects of levothyroxine and selenomethionine in euthyroid patients with Hashimoto’s thyroiditis. Thromb. Haemost. 108, 973–980 (2012).

    CAS  PubMed  Google Scholar 

  83. 83.

    Bhuyan, A. K., Sarma, D. & Saikia, U. K. Selenium and the thyroid: a close-knit connection. Indian. J. Endocrinol. Metab. 16, S354–S355 (2012).

    PubMed  PubMed Central  Google Scholar 

  84. 84.

    Anastasilakis, A. D. et al. Selenomethionine treatment in patients with autoimmune thyroiditis: a prospective, quasi-randomised trial. Int. J. Clin. Pract. 66, 378–383 (2012).

    CAS  PubMed  Google Scholar 

  85. 85.

    Eskes, S. A. et al. Selenite supplementation in euthyroid subjects with thyroid peroxidase antibodies. Clin. Endocrinol. 80, 444–451 (2014).

    CAS  Google Scholar 

  86. 86.

    de Farias, C. R. et al. A randomized-controlled, double-blind study of the impact of selenium supplementation on thyroid autoimmunity and inflammation with focus on the GPx1 genotypes. J. Endocrinol. Invest. 38, 1065–1074 (2015).

    PubMed  Google Scholar 

  87. 87.

    Pilli, T. et al. IFNγ-inducible chemokines decrease upon selenomethionine supplementation in women with euthyroid autoimmune thyroiditis: comparison between two doses of selenomethionine (80 or 160 mug) versus placebo. Eur. Thyroid J. 4, 226–233 (2015).

    CAS  PubMed  PubMed Central  Google Scholar 

  88. 88.

    Pirola, I., Gandossi, E., Agosti, B., Delbarba, A. & Cappelli, C. Selenium supplementation could restore euthyroidism in subclinical hypothyroid patients with autoimmune thyroiditis. Endokrynol. Pol. 67, 567–571 (2016).

    CAS  PubMed  Google Scholar 

  89. 89.

    Esposito, D. et al. Influence of short-term selenium supplementation on the natural course of Hashimoto’s thyroiditis: clinical results of a blinded placebo-controlled randomized prospective trial. J. Endocrinol. Invest. 40, 83–89 (2017).

    CAS  PubMed  Google Scholar 

  90. 90.

    Yu, L. et al. Levothyroxine monotherapy versus levothyroxine and selenium combination therapy in chronic lymphocytic thyroiditis. J. Endocrinol. Invest. 40, 1243–1250 (2017).

    CAS  PubMed  Google Scholar 

  91. 91.

    Wang, W. et al. Decreased thyroid peroxidase antibody titer in response to selenium supplementation in autoimmune thyroiditis and the influence of a SEPP gene polymorphism: a prospective, multicenter study in China. Thyroid 28, 1674–1681 (2018).

    CAS  Google Scholar 

  92. 92.

    van Zuuren, E. J., Albusta, A. Y., Fedorowicz, Z., Carter, B. & Pijl, H. Selenium supplementation for Hashimoto’s thyroiditis: summary of a Cochrane systematic review. Eur. Thyroid J. 3, 25–31 (2014).

    PubMed  Google Scholar 

  93. 93.

    Toulis, K. A., Anastasilakis, A. D., Tzellos, T. G., Goulis, D. G. & Kouvelas, D. Selenium supplementation in the treatment of Hashimoto’s thyroiditis: a systematic review and a meta-analysis. Thyroid 20, 1163–1173 (2010).

    CAS  PubMed  Google Scholar 

  94. 94.

    Winther, K. H., Wichman, J. E., Bonnema, S. J. & Hegedus, L. Insufficient documentation for clinical efficacy of selenium supplementation in chronic autoimmune thyroiditis, based on a systematic review and meta-analysis. Endocrine 55, 376–385 (2017).

    CAS  PubMed  Google Scholar 

  95. 95.

    Stagnaro-Green, A. Approach to the patient with postpartum thyroiditis. J. Clin. Endocrinol. Metab. 97, 334–342 (2012).

    CAS  PubMed  Google Scholar 

  96. 96.

    Negro, R. et al. The influence of selenium supplementation on postpartum thyroid status in pregnant women with thyroid peroxidase autoantibodies. J. Clin. Endocrinol. Metab. 92, 1263–1268 (2007).

    CAS  PubMed  Google Scholar 

  97. 97.

    Mao, J. et al. Effect of low-dose selenium on thyroid autoimmunity and thyroid function in UK pregnant women with mild-to-moderate iodine deficiency. Eur. J. Nutr. 55, 55–61 (2016).

    CAS  PubMed  Google Scholar 

  98. 98.

    Mantovani, G. et al. Selenium supplementation in the management of thyroid autoimmunity during pregnancy: results of the “SERENA study”, a randomized, double-blind, placebo-controlled trial. Endocrine 66, 542–550 (2019).

    CAS  PubMed  Google Scholar 

  99. 99.

    Brix, T. H., Kyvik, K. O., Christensen, K. & Hegedus, L. Evidence for a major role of heredity in Graves’ disease: a population-based study of two Danish twin cohorts. J. Clin. Endocrinol. Metab. 86, 930–934 (2001).

    CAS  PubMed  Google Scholar 

  100. 100.

    Wertenbruch, T. et al. Serum selenium levels in patients with remission and relapse of Graves’ disease. Med. Chem. 3, 281–284 (2007).

    CAS  PubMed  Google Scholar 

  101. 101.

    Arikan, T. A. Plasma selenium levels in first trimester pregnant women with hyperthyroidism and the relationship with thyroid hormone status. Biol. Trace Elem. Res. 167, 194–199 (2015).

    CAS  PubMed  Google Scholar 

  102. 102.

    Khong, J. J. et al. Serum selenium status in Graves’ disease with and without orbitopathy: a case-control study. Clin. Endocrinol. 80, 905–910 (2014).

    CAS  Google Scholar 

  103. 103.

    Dehina, N., Hofmann, P. J., Behrends, T., Eckstein, A. & Schomburg, L. Lack of association between selenium status and disease severity and activity in patients with Graves’ ophthalmopathy. Eur. Thyroid J. 5, 57–64 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  104. 104.

    Wang, Y. et al. Role of selenium intake for risk and development of hyperthyroidism. J. Clin. Endocrinol. Metab. 104, 568–580 (2019).

    PubMed  Google Scholar 

  105. 105.

    Effraimidis, G. & Wiersinga, W. M. Mechanisms in endocrinology: autoimmune thyroid disease: old and new players. Eur. J. Endocrinol. 170, R241–R252 (2014).

    CAS  PubMed  Google Scholar 

  106. 106.

    Calissendorff, J., Mikulski, E., Larsen, E. H. & Moller, M. A prospective investigation of Graves’ disease and selenium: thyroid hormones, auto-antibodies and self-rated symptoms. Eur. Thyroid J. 4, 93–98 (2015).

    CAS  PubMed  PubMed Central  Google Scholar 

  107. 107.

    Wang, L. et al. Effect of selenium supplementation on recurrent hyperthyroidism caused by Graves’ disease: a prospective pilot study. Horm. Metab. Res. 48, 559–564 (2016).

    CAS  PubMed  Google Scholar 

  108. 108.

    Leo, M. et al. Effects of selenium on short-term control of hyperthyroidism due to Graves’ disease treated with methimazole: results of a randomized clinical trial. J. Endocrinol. Invest. 40, 281–287 (2017).

    CAS  PubMed  Google Scholar 

  109. 109.

    Kahaly, G. J., Riedl, M., Konig, J., Diana, T. & Schomburg, L. Double-blind, placebo-controlled, randomized trial of selenium in Graves hyperthyroidism. J. Clin. Endocrinol. Metab. 102, 4333–4341 (2017).

    PubMed  Google Scholar 

  110. 110.

    Zheng, H. et al. Effects of selenium supplementation on Graves’ disease: a systematic review and meta-analysis. Evid. Based Complement. Alternat. Med. 2018, 3763565 (2018). A meta-analysis of trials of selenium supplementation in Graves disease.

    PubMed  PubMed Central  Google Scholar 

  111. 111.

    Marcocci, C. et al. Selenium and the course of mild Graves’ orbitopathy. N. Engl. J. Med. 364, 1920–1931 (2011). The only study that has investigated the effects of selenium supplementation in Graves ophthalmopathy and led to introduction of selenium supplementation in Graves ophthalmopathy.

    CAS  PubMed  Google Scholar 

  112. 112.

    Negro, R. et al. A 2016 Italian survey about the clinical use of selenium in thyroid disease. Eur. Thyroid J. 5, 164–170 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  113. 113.

    Winther, K. H., Papini, E., Attanasio, R., Negro, R. & Hegedüs, L. A 2018 European Thyroid Association survey on the use of selenium supplementation in Hashimoto’s thyroiditis. Eur. Thyroid J. (2019).

    Article  PubMed  Google Scholar 

  114. 114.

    Negro, R., Hegedus, L., Attanasio, R., Papini, E. & Winther, K. H. A 2018 European Thyroid Association survey on the use of selenium supplementation in Graves’ hyperthyroidism and Graves’ orbitopathy. Eur. Thyroid J. 8, 7–15 (2019).

    PubMed  Google Scholar 

  115. 115.

    Pearce, S. H. et al. 2013 ETA guideline: management of subclinical hypothyroidism. Eur. Thyroid J. 2, 215–228 (2013).

    CAS  PubMed  PubMed Central  Google Scholar 

  116. 116.

    Jonklaas, J. et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement. Thyroid 24, 1670–1751 (2014).

    PubMed  PubMed Central  Google Scholar 

  117. 117.

    Lazarus, J. et al. 2014 European Thyroid Association guidelines for the management of subclinical hypothyroidism in pregnancy and in children. Eur. Thyroid J. 3, 76–94 (2014).

    CAS  PubMed  PubMed Central  Google Scholar 

  118. 118.

    Alexander, E. K. et al. 2017 guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid 27, 315–389 (2017).

    PubMed  PubMed Central  Google Scholar 

  119. 119.

    Kahaly, G. J. et al. 2018 European Thyroid Association guideline for the management of Graves’ hyperthyroidism. Eur. Thyroid J. 7, 167–186 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  120. 120.

    Ross, D. S. et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 26, 1343–1421 (2016).

    Google Scholar 

  121. 121.

    Bartalena, L. et al. The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy guidelines for the management of Graves’ orbitopathy. Eur. Thyroid J. 5, 9–26 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  122. 122.

    O’Toole, D., Raisbeck, M., Case, J. C. & Whitson, T. D. Selenium-induced “blind staggers” and related myths. A commentary on the extent of historical livestock losses attributed to selenosis on western US rangelands. Vet. Pathol. 33, 104–116 (1996).

    Google Scholar 

  123. 123.

    Yang, G. Q., Wang, S. Z., Zhou, R. H. & Sun, S. Z. Endemic selenium intoxication of humans in China. Am. J. Clin. Nutr. 37, 872–881 (1983).

    CAS  PubMed  Google Scholar 

  124. 124.

    Yang, G. & Zhou, R. Further observations on the human maximum safe dietary selenium intake in a seleniferous area of China. J. Trace Elem. Electrolytes Health Dis. 8, 159–165 (1994).

    CAS  PubMed  Google Scholar 

  125. 125.

    Kristal, A. R. et al. Baseline selenium status and effects of selenium and vitamin E supplementation on prostate cancer risk. J. Natl Cancer Inst. 106, djt456 (2014).

    PubMed  PubMed Central  Google Scholar 

  126. 126.

    Stranges, S. et al. Effects of long-term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Ann. Intern. Med. 147, 217–223 (2007).

    PubMed  Google Scholar 

  127. 127.

    Duffield-Lillico, A. J. et al. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. J. Natl Cancer Inst. 95, 1477–1481 (2003).

    CAS  PubMed  Google Scholar 

  128. 128.

    Kim, J. et al. Association between serum selenium level and the presence of diabetes mellitus: a meta-analysis of observational studies. Diabetes Metab. J. 43, 447–460 (2019).

    PubMed  PubMed Central  Google Scholar 

  129. 129.

    Kohler, L. N. et al. Selenium and type 2 diabetes: systematic review. Nutrients 10, E1924 (2018).

    PubMed  Google Scholar 

  130. 130.

    Jacobs, E. T. et al. Selenium supplementation and insulin resistance in a randomized, clinical trial. BMJ Open. Diabetes Res. Care 7, e000613 (2019).

    PubMed  PubMed Central  Google Scholar 

  131. 131.

    Stranges, S. et al. Effect of selenium supplementation on changes in HbA1c: results from a multiple-dose, randomized controlled trial. Diabetes Obes. Metab. 21, 541–549 (2019).

    CAS  PubMed  Google Scholar 

  132. 132.

    Steinbrenner, H., Speckmann, B., Pinto, A. & Sies, H. High selenium intake and increased diabetes risk: experimental evidence for interplay between selenium and carbohydrate metabolism. J. Clin. Biochem. Nutr. 48, 40–45 (2011).

    CAS  PubMed  Google Scholar 

  133. 133.

    Speckmann, B. et al. Selenoprotein P expression is controlled through interaction of the coactivator PGC-1α with FoxO1a and hepatocyte nuclear factor 4α transcription factors. Hepatology 48, 1998–2006 (2008).

    CAS  PubMed  Google Scholar 

  134. 134.

    Misu, H. et al. A liver-derived secretory protein, selenoprotein P, causes insulin resistance. Cell Metab. 12, 483–495 (2010).

    CAS  PubMed  Google Scholar 

  135. 135.

    Hellwege, J. N. et al. Genetic variants in selenoprotein P plasma 1 gene (SEPP1) are associated with fasting insulin and first phase insulin response in Hispanics. Gene 534, 33–39 (2014).

    CAS  PubMed  Google Scholar 

  136. 136.

    Zhang, Q. et al. Selenium levels in community dwellers with type 2 diabetes mellitus. Biol. Trace Elem. Res. 191, 354–362 (2019).

    CAS  PubMed  Google Scholar 

  137. 137.

    Scientific Committee on Food & Scientific Panel on Dietetic Products, Nutrition and Allergies. Tolerable upper intake levels for vitamins and minerals. (European Food Safety Authority, 2006).

  138. 138.

    Kipp, A. P. et al. Revised reference values for selenium intake. J. Trace Elem. Med. Biol. 32, 195–199 (2015).

    CAS  PubMed  Google Scholar 

  139. 139.

    Hurst, R. et al. Establishing optimal selenium status: results of a randomized, double-blind, placebo-controlled trial. Am. J. Clin. Nutr. 91, 923–931 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  140. 140.

    Winther, K. H., Bonnema, S. J. & Hegedus, L. Is selenium supplementation in autoimmune thyroid diseases justified? Curr. Opin. Endocrinol. Diabetes Obes. 24, 348–355 (2017).

    CAS  PubMed  Google Scholar 

  141. 141.

    Winther, K. H. et al. The chronic autoimmune thyroiditis quality of life selenium trial (CATALYST): study protocol for a randomized controlled trial. Trials 15, 115 (2014).

    PubMed  PubMed Central  Google Scholar 

  142. 142.

    Watt, T. et al. The thyroid-related quality of life measure ThyPRO has good responsiveness and ability to detect relevant treatment effects. J. Clin. Endocrinol. Metab. 99, 3708–3717 (2014).

    CAS  PubMed  Google Scholar 

  143. 143.

    Watt, T. et al. Development of a short version of the Thyroid-Related Patient-Reported Outcome ThyPRO. Thyroid 25, 1069–1079 (2015).

    PubMed  Google Scholar 

  144. 144.

    Winther, K. H. et al. Disease-specific as well as generic quality of life is widely impacted in autoimmune hypothyroidism and improves during the first six months of levothyroxine therapy. PLoS One 11, e0156925 (2016).

    PubMed  PubMed Central  Google Scholar 

  145. 145.

    Watt, T. et al. Selenium supplementation for patients with Graves’ hyperthyroidism (the GRASS trial): study protocol for a randomized controlled trial. Trials 14, 119 (2013).

    CAS  PubMed  PubMed Central  Google Scholar 

  146. 146.

    Seale, L. A., Ogawa-Wong, A. N. & Berry, M. J. Sexual dimorphism in selenium metabolism and selenoproteins. Free. Radic. Biol. Med. 127, 198–205 (2018). A review highlighting the importance of considering sex differences in selenium metabolism and selenoprotein action when analysing laboratory and clinical data.

    CAS  PubMed  PubMed Central  Google Scholar 

  147. 147.

    Hybsier, S. et al. Sex-specific and inter-individual differences in biomarkers of selenium status identified by a calibrated ELISA for selenoprotein P. Redox Biol. 11, 403–414 (2017).

    CAS  PubMed  Google Scholar 

  148. 148.

    Prasad, V., Gall, V. & Cifu, A. The frequency of medical reversal. Arch. Intern. Med. 171, 1675–1676 (2011).

    PubMed  Google Scholar 

  149. 149.

    Rayman M. P. & Duntas L. H. in The Thyroid and Its Diseases: A Comprehensive Guide for the Clinician (eds Luster, M., Duntas, L. H. & Wartofsky, L.) 109–126 (Springer International, 2019).

Download references


The authors acknowledge the long-term collaboration within the ThyQoL group (T. Watt, Å.K. Rasmussen, P. Cramon, J. Bjørner, M. Grønvold, F. Pociot, U. Feldt-Rasmussen), which at present, among a number of efforts, is investigating the potential benefit of selenium supplementation in Graves disease and chronic autoimmune thyroiditis.

Author information




All the authors researched data for the article, made substantial contributions to the discussion of content and reviewed and/or edited the manuscript before submission. K.H.W., M.P.R. and L.H. wrote the article.

Corresponding author

Correspondence to Laszlo Hegedüs.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information



Proteins that include a selenocysteine residue in their amino acid sequence.

Chronic autoimmune thyroiditis

Patients with thyroid autoantibodies with or without goitre and with or without hypothyroidism.

Selenium speciation

The chemical form or compound in which selenium occurs in food, in the environment or in the body.

Neutron activation analysis

An analytical method that uses a neutron beam to determine the concentrations of elements in a substance.

Blind staggers

Severe selenosis among animals, particularly livestock, characterized by impaired vision and an unsteady gait.


Poisoning due to excessive intake of selenium.

Thyroid-Specific Patient Reported Outcome (ThyPRO) questionnaire

The first thyroid disease-specific questionnaire developed to measure health-related quality of life across the spectrum of benign thyroid diseases.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Winther, K.H., Rayman, M.P., Bonnema, S.J. et al. Selenium in thyroid disorders — essential knowledge for clinicians. Nat Rev Endocrinol 16, 165–176 (2020).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing